Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy

BACKGROUND: Checkpoint inhibitor immunotherapy is becoming an effective treatment modality for an increasing number of malignancies. As a result, autoinflammatory side-effects are also being observed more commonly in the clinic. We are currently unable to predict which patients will develop more sev...

Descripción completa

Detalles Bibliográficos
Autores principales: Lowe, Jared R., Perry, Daniel J., Salama, April K. S., Mathews, Clayton E., Moss, Larry G., Hanks, Brent A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5170902/
https://www.ncbi.nlm.nih.gov/pubmed/28031819
http://dx.doi.org/10.1186/s40425-016-0196-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5170902/
https://www.ncbi.nlm.nih.gov/pubmed/28031819
http://dx.doi.org/10.1186/s40425-016-0196-z

Ejemplares similares